INNATE PHARMA : INNATE PHARMA (2 phases III et 7 phases II)

EL_CAMINO

09 févr. 2022 •12:48

MONALIZUMAB (NKG2A):
Option de paiement 100M$ à Phase III – Paiement réglementaires jusqu’à 400M$ - Paiements commerciaux jusqu’à 425M$ - Royalties: Deux digits – Co-promotion : IPH participe aux profits en EU en co-paiement de la phase III.
-INTERLINK-1 (Phase 3) - NCT04590963 (AstraZeneca): Recurrent or Metastatic HNSCC, 2L (Patients: 600) – reste 50M$ à payer
-PACIFIC-9 (Phase 3) - NCT05221840 (AstraZeneca): Effects of Durvalumab wth Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients With Stage III NSCLC (Patients: 1000) – 100M$ à payer sur 1er patient
-IPH2201-203 (Phase 1 / 2) - NCT02643550 (Innate Pharma): Recurrent or Metastatic HNSCC, post IO and/or platinum or naïve (Patients: 140)
-UPSTREAM (Phase 2) - NCT03088059 (EORTC): Recurrent or Metastatic after first line platinum-based chemotherapy HNSCC (Patients: 340)
-NeoCOAST (Phase 2) - NCT03794544 (AstraZeneca): Resectable early stage (I to IIIA) NSCLC (Patients: 80)
-NeoCOAST-2 (Phase 2) - NCT05061550 (AstraZeneca): Resectable early stage (II to IIIA) NSCLC (Patients: 140)
-PIONeeR (Phase 2) - NCT03833440 (AP-HM): Advanced stage or recurrent NSCLC (Patients: 120)
-D419NC00001 (Phase 1 / 2) - NCT02671435 (AstraZeneca): Advanced solid tumours (Patients: 381)
-PIRAT (Phase 1) - NCT02921685 (Institut Paoli-Calmettes): Hematologic Malignancies (Patients : 18)

AVDORALIMAB (C5aR1):
-IPH5401 (Phase 2) - NCT04563923 (CHU Nice): Bullous Pemphigoid (Patients: 40)

LACUTAMAB (KIR3DL2):
-TELLOMAK (Phase 2) - NCT03902184 (Innate Pharma): R/R Sezary Syndrome and Stage IB-IV Mycosis Fungoides (Patients: Up to 150) Cohort 1: R/R Sezary Syndrome
-KILT (Phase 2) - NCT04984837 (LYSA): R/R Peripheral T Cell Lymphoma (Patients: 56)

IPH6101 (CD123/NKp46/CD16a) – ANKET
Option de paiement suite à l’atteinte d’objectifs de développement et de commercialisation pouvant atteindre 400 millions d’euros ainsi qu’à des redevances assises sur les ventes nettes. 7M$ en janvier 2021 pour les études précliniques – Rien de communiqué sur la phase 1 / 2.
-SAR443579 (Phase 1 / 2) - NCT05086315 (Sanofi): B-cell Acute Lymphoid Leukemia High Risk-Myelodisplasia (Patients: 82)

Reste:
IPH5201-CD39 (Phase 1) - NCT04261075 (AstraZeneca): Advanced Solid Tumors (Patients: 204)
IPH5301-CD73 – NT??? (Innate Pharma): Metastatic Breast, Pancreatic, Gastric, Lung, Ovary, Oesophageal, Endometrial cancer, Advanced Solid Tumor (Patients: 27)
IPH62 – Co-development AZN – Pre-clinical
IPH25 and IPH26 (Siglec-9) – Co-development AZN – Pre-clinical
IPH43 (MICA/B ADC) – Co-development AZN – Pre-clinical